Carmat - Update on debt repayment negotiations
An agreement in principle has been reached with BNP Paribas and Bpifrance regarding the rescheduling of the 2 state-guaranteed loans contracted with those. This agreement is conditional, notably on the implementation of the agreement reached with the EIB.Remember that Carmat reached a conditional agreement with the EIB in January 2024 which provides for the postponement of the repayment of its loan to 2026.Those agreements in principle are reassuring and constitute a necessary step in extending the financial visibility of the company. Remember however that even if those are finalized – which the CEO is confident will happen - financing remainsCarmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.